header logo image


Page 582«..1020..581582583584..590600..»

Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? – InvestorsObserver

April 24th, 2020 5:49 pm

Mesoblast limited (MESO) is near the top in its industry group according to InvestorsObserver. MESO gets an overall rating of 82. That means it scores higher than 82 percent of stocks. Mesoblast limited gets a 95 rank in the Biotechnology industry. Biotechnology is number 10 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Mesoblast limited (MESO) stock is trading at $16.61 as of 10:30 AM on Friday, Apr 24, an increase of $10.16, or 157.52% from the previous closing price of $6.45. The stock has traded between $14.33 and $20.57 so far today. Volume today is above average. So far 12,327,011 shares have traded compared to average volume of 428,508 shares.

To screen for more stocks like MESO click here.

Go here to read the rest:
Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? - InvestorsObserver

Read More...

Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? – The News Heater

April 24th, 2020 5:49 pm

Vir Biotechnology, Inc. (NASDAQ:VIR) went up by 3.56% from its latest closing price when compared to the 1-year high value of $75.00 and move down -140.77%, while VIR stocks collected +6.21% of gains with the last five trading sessions. Press Release reported on 04/15/20 that VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

VIR stocks went up by 6.21% for the week, with the monthly drop of -4.89% and a quarterly performance of 83.45%. The simple moving average for the period of the last 20 days is 0.29% for VIR stocks with the simple moving average of 44.30% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -58.47% of loss for the given period.

The stock volatility was left at 11.09%, however, within the period of a single month, the volatility rate increased by 7.37%, while the shares surge at the distance of +1.30% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +70.78% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +6.21%. In addition, Vir Biotechnology, Inc. saw 147.71% in overturn over the period of a single year with a tendency to cut further gains.

The current profitability levels are settled at -2110.98 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -61.54, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Visit link:
Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? - The News Heater

Read More...

Insights on the Worldwide Biotechnology Reagents Industry to 2024 – Drivers, Challenges and Trends – ResearchAndMarkets.com – Business Wire

April 24th, 2020 5:49 pm

DUBLIN--(BUSINESS WIRE)--The "Global Biotechnology Reagents Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The biotechnology reagents market is poised to grow by $ 37.87 bn during 2020-2024 progressing at a CAGR of 8% during the forecast period. The report on the biotechnology reagents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the presence of high-throughput and novel technologies and high usage of biotechnology reagents in diagnostic and therapeutic applications. In addition, the presence of high-throughput and novel technologies is anticipated to boost the growth of the market as well.

This study identifies the increasing R&D investments by federal agencies and biotechnology firms as one of the prime reasons driving the biotechnology reagents market growth during the next few years.

Companies Mentioned

Key Topics Covered:

1. Executive Summary

2. Market Landscape

3. Market Sizing

4. Five Forces Analysis

5. Market Segmentation by Technology

6. Customer landscape

7. Geographic Landscape

8. Drivers, Challenges, and Trends

9. Vendor Landscape

10. Vendor Analysis

11. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/jdmnpl.

See original here:
Insights on the Worldwide Biotechnology Reagents Industry to 2024 - Drivers, Challenges and Trends - ResearchAndMarkets.com - Business Wire

Read More...

Biotech and Pharmaceutical Stocks Beat the Market in Recessions – Barron’s

April 24th, 2020 5:49 pm

Text size

Looking for a safe harbor during the Covid-19 pandemic? The biotech and pharmaceutical industries deserve a close look, according to SVB Leerink analyst Geoffrey Porges.

The indexes that track the biotech and pharmaceutical sectors outperformed the market in the 2001, 2008-09, and current recessions, he wrote in a Friday morning note.

On average, the biotechnology Indexes declined -1% during the three economic downturns, compared with the pharmaceutical indexs -10% and the S&P 500 indexs -20%. On a relative basis, biotech and pharmaceutical Indices outperformed the S&P 500 by 18% and 10%, respectively, Porges noted.

One likely explanation: People need their medicine, even in a recession. Porges cited published papers showing that pharmaceutical sales volume stayed steady in the U.S. during the 2008-09 recession.

So far this year, biotech indexes and exchange-traded funds have vastly outperformed the market. While the S&P 500 is down 13.4% since the start of the year, the iShares Nasdaq Biotechnology ETF (ticker: IBB) is up 2.2%. The SPDR S&P Biotechnology ETF (XBI) is down 1.4%, while the Nasdaq Biotechnology Index (NBI) is up 2.3%.

Pharmaceutical indexes have also performed well. The NYSE Arca Pharmaceutical index is down 1.1%, while the S&P 500 Pharmaceuticals index is down 0.5%.

Those performances have been boosted by strong showings from large-cap biotech companies like Gilead Sciences (GILD), which is up 19.7% so far this year on excitement over its experimental Covid-19 therapy remdesivir, and Moderna (MRNA), which is up a startling 142.5% so far this year over its Covid-19 vaccine, which is in clinical trials.

Major pharmaceutical companies have also outperformed. Johnson & Johnson (JNJ) is up 6.6%, while Eli Lilly (LLY) is up 21.7%. The company clocked a new 52-week high on Friday morning.

Porges note suggests that all this tracks with the recent history of recessions.

Our analysis of historical recessions suggested that the biotech and pharma indices (and stocks) significantly outperformed the broad market (S&P 500), despite the greater P/E multiple compressions in the healthcare indices, he wrote.

The iShares Nasdaq Biotechnology ETF was up 0.6% in recent trading, while the S&P 500 was up 0.4%.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

Continued here:
Biotech and Pharmaceutical Stocks Beat the Market in Recessions - Barron's

Read More...

Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months – The InvestChronicle

April 24th, 2020 5:49 pm

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $31.15 to be very precise. The Stock rose vividly during the last session to $31.4 after opening rate of $29.55 while the lowest price it went was recorded $29.55 before closing at $30.08.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.47% during the 52-week period from high price, and 167.37% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.56 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 147.71%, having the revenues showcasing 83.45% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.41B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 24.32, with a change in the price was noted +19.25. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +161.76% for the period of last 100 days, recording 780,574 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 25.56%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 31.58%. In the last 20 days, the companys Stochastic %K was 27.22% and its Stochastic %D was recorded 25.85%.

Bearing in mind the latest performance of Vir Biotechnology, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 147.71%. The shares increased approximately by 1.57% in the 7-day charts and went up by 6.21% in the period of the last 30 days. Common stock shares were driven by 83.45% during last recorded quarter.

More:
Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months - The InvestChronicle

Read More...

Impact of COVID-19 Outbreak on Global Briefing 2019 Pharmaceutical and Biotechnology Machines Industry Analyzer Technique, Advancements, Market Size,…

April 24th, 2020 5:49 pm

The report on the Pharmaceutical and Biotechnology Machines market provides a birds eye view of the current proceeding within the Pharmaceutical and Biotechnology Machines market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Pharmaceutical and Biotechnology Machines market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Pharmaceutical and Biotechnology Machines market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Pharmaceutical and Biotechnology Machines market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Pharmaceutical and Biotechnology Machines market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2553414&source=atm

The major players profiled in this Pharmaceutical and Biotechnology Machines market report include:

The following manufacturers are covered:Air LiquideLinde HealthcarePraxairAir ProductsTaiyo Nippon SansoMatheson GasAtlas Copco ABMesser GroupSOL GroupNorcoSicgil India LimitedShenzhen GaofaShenwei MedicalBeijing OrientNanning Lantian

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeOxygenNitrous OxideMedical AirOthers(Nitrogen, Carbon Dioxide and Helium)

Segment by ApplicationHospitals (Labs & Clinics)Home HealthcareUniversities/Research InstitutionsPharmaceutical & Biotechnology Industries

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2553414&licType=S&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2553414&source=atm

Excerpt from:
Impact of COVID-19 Outbreak on Global Briefing 2019 Pharmaceutical and Biotechnology Machines Industry Analyzer Technique, Advancements, Market Size,...

Read More...

Costa Rica prepares to develop its own coronavirus tests; will announce next steps in facing crisis – The Tico Times

April 24th, 2020 5:49 pm

Costa Rica plans to develop its own test for the coronavirus, President Carlos Alvarado announced Thursday afternoon.

The Costa Rican government is also preparing to announce a roadmap for easing restrictions against the spread of COVID-19.

In addition to the latest coronavirus data, heres what you should know from todays press conference:

The National Center of Biotechnology Innovations is developing a test for the coronavirus that could reduce the countrys burden on international kits, President Alvarado said.

Today, we are announcing that Costa Rica is developing its own tests for COVID-19, here in our country, he said. Facing the situation of high international demand for tests, we have the capability to create them here.

Randall Loaiza, director of the biotechnology laboratory, gave a brief demonstration of the test.

Genetic material will first be extracted from a mucous sample, separating RNA from the rest of the sample.After a purification process, the RNA will be placed into a PCR machine and allowed to reproduce, at which point the presence (or lack thereof) of SARS-CoV-2 can be detected.

By producing its own reagents or by acquiring reagents that are in lower demand, Costa Rica could minimize its dependency on solutions that are in short supply worldwide. (This is similar to a strategycreated by virologists in England.)

Its not just that we want to have a home-brew solution, Loaiza said. Its a need to have a home-brew solution that meets the same standards as the kits.

Theteam working on the new test is comprised of Costa Rican biologists, physicists, virologists, geneticists and biotechnologists.The National Center of Biotechnology Innovations hopes to have its tests approved and distributed in six weeks.

This demonstrates the quality of our human talent and our science, and the solidarity of our country, President Alvarado said.

Costa Rican authorities will announce on Monday plans for the country to ease restrictions that have been established to slow the spread of COVID-19.

The roadmap is designed to allow Costa Rica to gradually relax measures while minimizing the countrys risk for a surge in cases.

The situation of the pandemic is, thanks to all of our efforts, under control, President Alvarado said. But it is a very fragile control.

President Alvarado urged Costa Ricans not to let down their guards and warned that normal wont be the same as it was before.

In response to the coronavirus, Costa Rica has suspended mass gatherings, closed its borders to non-residents and established vehicular restrictions, among other measures.Costa Rica has announced seven-straight decreases in known active coronavirus cases.

Costa Rica coronavirus cases. Click for full size. Tico Times graph.

On May 4, President Alvarado will deliver his annual address to the Legislative Assembly Costa Ricas version of a State of the Union.

Alvarado said Thursday that his speech will focus on how Costa Rica can reactivate its economy and respond with unity to the coronavirus crisis.

Were on one team: Team Costa Rica, he said.If were not careful, we can become a country divided. We have to avoid that at all costs.

Read more here:
Costa Rica prepares to develop its own coronavirus tests; will announce next steps in facing crisis - The Tico Times

Read More...

Boosting the Immune System Really Does Help With COVID-19, Experts Say – Phoenix New Times

April 24th, 2020 5:48 pm

According to some of the more dramatic pandemic predictions, as many as 150 million Americans will come down with COVID-19 before a vaccine becomes widely available. While avoiding it altogether is the ideal scenario, as the virus continues to spread, for many, infection is inevitable.

Given that unfortunate reality, building up a personal defense system against an invisible enemy is paramount, according to the experts.

In March, Banner Health published a blog post: How You Can Boost Your Immune System, with the message: A strong immune system is the ultimate defense against illness, whether its COVID-19, seasonal flu, or something else. The posts advice is largely mundane: Get eight hours of sleep, eat nutritious foods, exercise, hydrate, and do what you can to reduce stress in an incredibly stressful time.

Most people understand that adopting healthier habits is a good idea, but can these habits really boost your immune system so that a coronavirus infection looks more like, say, a common cold? Jessica Lancaster, an immunologist researcher at the Mayo Clinic, thinks its a distinct possibility.

If you had two people with the same virus exposure and very similar genetic makeup, Lancaster said, and if one had been better overall sleeping, eating well, and exercising that person would most likely be much better off than the person who is not caring for themselves as well.

The microscopic novel coronavirus typically enters the body through the nose, she said. From there, it begins a deliberate and dangerous process of multiplying and penetrating deeper down the respiratory tract and into the bloodstream. A spry immune system bolstered by exercise, healthy food, and plenty of sleep will harass the virus before it wreaks the kind of havoc that requires hospitalization, ICU admission, or a ventilator.

Essentially, the immune system is a collection of cells, surveilling our body for unwelcome visitors: viruses, bacteria, various toxins, and cancer. When something isnt right, alarm bells go off and the immune system springs into action to make things right.

Jessica Lancaster, immunologist at the Mayo Clinic

YouTube/Mayo Clinic

Our immune systems ability to react to alarm bells and fight off foreign intruders depends on a multitude of factors. Among them are our age, where we live, what we do for work, and three biggies: good sleep, low stress, and healthy eating. These things have a profound effect on two major contributors to our immune systems sharpness: chronic inflammation and cortisol levels.

In the case of COVID-19, the virus hijacks lung cells and eventually damages them to where they become inflamed. But when there is chronic inflammation in people, such as those with preexisting conditions like heart disease or lung disease, the immune cells are worn out or lulled to sleep.

In these cases, Lancaster said, [immune cells] are kind of used to hearing these signals over and over again. When they have to actually respond to something, they're already exhausted.

For example, if you are regularly exposed to toxic chemicals that cause inflammation, like cigarette smoke, you can have a boy that cried wolf situation, where the body gets jaded to these constant warning signs of trouble and is slower to respond.

For someone with COVID-19, any kind of delayed immune response can be catastrophic.

When you have something that is quite aggressive like coronavirus, which can strike really quickly if you have a lagging immune response, that can be devastating because by the time everything is mobilized, its too late. There's too much damage to the lungs, Lancaster said.

One simple way to avoid inflammation is to avoid overeating. If you eat too many calories, it can be hard for your body to regulate its blood sugar. And that leads to inflammation, Lancaster said, adding that this kind of blood sugar-induced inflammation tends to affect the kidneys, liver, and pancreas.

When it comes to supplements, Lancaster is ambivalent. But she admitted that when she gets sick herself, she takes zinc lozenges. She cited some inconclusive evidence that Vitamin C may have some antiviral properties or may be simply reducing inflammation across the body.

Cortisol is another of the bodys loud alarm bells. It is our primary stress hormone, and according to Lancaster, it can cause drastic changes to the way that your cells can function on a genetic level. A burst of cortisol here or there can help you spring into action to avoid a threat, but too much, too often can leave your body stuck in an uncomfortable, unhealthy kind of overdrive.

Lab research shows that immune cells can't fight viruses as well when they are injected with cortisol. In 2018, researchers at the University of Kent found cortisol levels to be a critical factor at play in leukemia cases, showing that the stress hormone hinders the immune systems ability to incapacitate intruders before they really get destructive.

Reading, meditating, and especially exercising may lower cortisol levels in people.

Exercising has the added benefit of helping you get your eight hours of sleep, all of which helps reduce inflammation and regulate stress hormones.Last week, a cardiovascular researcher at the University of Virginia released findings suggesting that an antioxidant that is naturally released during exercise can significantly reduce the risk of suffering fromacute respiratory distress syndrome, a severe problem that occurs in 20 to 42 percent of hospitalized COVID-19 patients. Exercise, the research found, boosts production of an antioxidant known as extracellular superoxide dismutase, or EcSOD, which "hunts" atomic free radicals that can harm the body's cells.

Beth Jacobs

University of Arizona

"We cannot live in isolation forever, said Zhen Yan of the University of Virginia School of Medicine in an April 15 University of Virginia news release. "Regular exercise has far more health benefits than we know. The protection against this severe respiratory disease condition is just one of the many examples.

Beth Jacobs, a nutritional epidemiologist at the University of Arizona, is wary about making any promises about how any type of immune boosting can influence ones chances of coming down with a bad case of the virus.

"We know essentially nothing about COVID19 yet," she said in a recent interview.

In lieu of more specific knowledge about the virus, she echoes Lancasters sentiments about the importance of healthy habits. When it comes to immunity, she said, it is all about the three interlocked concepts, which are diet, physical activity, and sleep.

Essentially, [sleep] is the time when you're repairing what's happened during the day, Jacobs said. It allows you to heal up to take on the next day.

While science has yet to uncover the inner workings of sleep, Jacob says we can infer its value from its incredible cost. Our ancient ancestors risked being eaten while they laid motionless for hours a day for it, she pointed out.

She urges persistence and patience in developing new, healthy habits, stressing that we are still at the very beginning of the pandemic. Try new recipes and get outside, Jacobs urged.

Use the time to go outside and walk," she said. "And if you've never walked before, just take a 10-minute walk, and then a 15-minute walk next week. Just keep going."

See the article here:
Boosting the Immune System Really Does Help With COVID-19, Experts Say - Phoenix New Times

Read More...

COVID-19 kills more men than women. The immune system may be why – Science News

April 24th, 2020 5:48 pm

With more men than women developingsevere illness and dying from COVID-19, sex differences that influence theimmune system may offer answers.

The bias in COVID-19 deaths appearedin the first reports out of China and has also been revealed in countries thatbreak down their mortality data by sex. Of Italys 21,551 deaths recorded as ofApril 20, 64 percent were men. In Spain, 59 percent of the 12,634 deaths as of April 21 occurred in men. Germany had recorded 4,598deaths by April 21, with 58 percent in men.

The United States does notseparate out national COVID-19 mortality by sex, but some states do. New York hasthe highest number COVID-19 deaths in the country, and as of April 21, 60 percent of 15,302 deaths were in men.

Some of that discrepancycould be because men are more likely than women to have other health problems,such as hypertension and diabetes. These are among the underlying conditionsthat raise the risk for severe COVID-19 disease, the U.S. Centers for Disease Control and Preventionreported April 3.

Another possible culprit isthe immune system itself. The many proteins that work together to defend thebody against viruses do not operate exactly the same way in males and females. Thosebiological differences, driven by sex hormones and genes, may be guarding somewomen from the deadliest complications of COVID-19.

Scientists and journalists share a core belief in questioning, observing and verifying to reach the truth. Science News reports on crucial research and discovery across science disciplines. We need your financial support to make it happen every contribution makes a difference.

In general, females mount astronger immune response than males, studies have found. This makes womenoverall less susceptible to viral infections than men, although how each individualfares is another matter. A stronger immune response also means females are morelikely to develop autoimmune diseases, when the immune system attacks ones owntissue; conversely, a toned down immune response makes males more prone tohaving a host of malignant cancers.

The sources of the stronger femaleimmune response can be found in both the innate and adaptive immune systems,says Sabra Klein, a virologist at the Johns Hopkins University Bloomberg Schoolof Public Health. The innate system provides the first response against a virus,while the adaptive systems contribution is slightly delayed by the time neededto ramp up antibody production against a new intruder.

One component of the innateimmune system is called toll-like receptor 7. This protein can recognizemolecules found on viruses, thereby outing the pathogens as foreign. The genefor toll-like receptor 7 resides on the X chromosome. Because females have twocopies of the X, the body silences one (SN: 4/8/03),allowing for the right dose of X chromosome genes. But some genes escape the shutdown, and there is evidence that this is true for the gene for toll-likereceptor 7, researchers reported in Science Immunology in 2018. That canlead to more of the protein being made, giving females more guards looking outfor intruders.

Having more toll-likereceptor 7 can help jump start and enhance the next steps of the innate immune system.You want fast recognition, you want fast responses, Klein says. This is howyou start to activate the army of immune responses that are going to be neededto clear an infection. One of those steps is the release of interferons,proteins that direct major factions of the bodys immune response. In studiesthat measure levels of interferons in blood or in cells grown in a dish, researchersoverall see greater production of these interferons in females as comparedwith males, says Klein.

As the adaptive immunesystem gears up, women can get a boost over men again. The amount of antibodyproduced, as well as the quality of those antibodies, or the strength withwhich they bind to the virus, tends to be greater in females compared withmales, Klein says. Female mice produced more neutralizing antibodies the type which stop an infection by preventing thevirus from entering cells and more total antibodies against influenza A virus after infection comparedwith males, Klein and colleagues reported in Vaccine in 2011.

The female hormone estrogenalso influences the innate and adaptive immune systems. The hormone can regulatea variety of different genes for immune system proteins. For example, estrogen canstimulate the production of interferons, says Klein. And some of the genes thatare associated with directing the response of B cells, which make antibodies,are regulated by estrogen.

All of these findings comefrom research with other viruses, and havent yet been studied in the contextof COVID-19, Klein says, but they provide us with some clues. At this point,some of the best clues as to why there are discrepancies in how men and womenfare with COVID-19 may come from a study of the disease SARS in mice. The virus that causes SARS shares similarities with the culprit behind COVID-19,SARS-CoV-2 (SN: 2/3/20). And there isevidence that during the SARS epidemic of 2002-2003, which had close to 800deaths, men had a higher case fatality rate than women.

Its helpful to study sexdifferences in mice because it takes behavioral influences out of the equation,says Stanley Perlman, a virologist at the University of Iowa in Iowa City. Forexample, as reports from China indicated that more men than women were havingsevere cases of COVID-19, some also noted this could be due to the fact thatmore Chinese men than women smoke. China was also among the five countries thatSARS cases were concentrated in.

Perlmans team compared how male and female mice did when infected with a mouse-adapted version of SARS-CoV,the virus that causes SARS, and reported the results in the Journal of Immunology in 2017. Among middle-agedmice, those 8 to 9 months old, all of the males died within eight days of beinginfected, but only 10 percent of the females did by day 12. Males had higheramounts of the virus in their lungs than females did, suggesting the maleswerent clearing the virus effectively. The males also had a prolonged,unhelpful inflammatory response.

Headlines and summaries of the latest Science News articles, delivered to your inbox

When the research teamremoved the ovaries from 12 female mice to prevent estrogen from being made, about85 percent of the mice died after infection, compared with close to 20 percentof 12 females with their ovaries. Without estrogen, the female mice were nowas sensitive to the infection as male mice, Perlman says. While I wouldntclaim its the whole story, estrogen is a big part of the story.

Klein and Perlman both haveplans to study differences in the male and female response to COVID-19. In caseswhen the bodys own immune response contributes to a viral disease, it might beexpected women would fare worse, Klein says, because a strong immune responsecan lead to too much damaging inflammation. And with COVID-19, theres a lot ofconcern about the detrimental effect of increased inflammation in the lungs.

But what happens during COVID-19might be different. This aberrant inflammation might be higher in males thanfemales, Klein says.

See the original post here:
COVID-19 kills more men than women. The immune system may be why - Science News

Read More...

Covid-19 immunity and testing, explained – Vox.com

April 24th, 2020 5:48 pm

The Covid-19 coronavirus meets its most formidable foe the moment it enters the human body.

The immune system is waiting, ready for action, and it determines who dies and who survives. It is why the vast majority of the infected have recovered from the disease.

Yet one of the most important unknowns is why some peoples immune systems are up to the task of clearing out the virus while others are sluggish or overreact, leading to death. Just as vexing:

Its helpful in thinking through these unanswered questions to understand how the immune system works (collectively and in individuals), how immunity testing works, and how immunity to similar viruses changes over time. Its also comforting to know that if you get Covid-19, your body will try very, very hard to save you. And if it doesnt, it could be because it tried too hard.

So here is a guide to the immune system: antibodies, serological tests, reinfection, and immunological memory, explained.

The first thing to know about the immune system is that it is not simple. At all.

A huge array of cells and chemicals your body produces work in concert to clear a foreign invader from your body. Theres a lot of elegance to this whole system, Akiko Iwasaki, an immunologist at the Yale School of Medicine, says. Its like an orchestra. All these cells and chemicals have to work in concert each with a different part to play to defeat the virus.

A viral infection begins when a virus enters a cell of your body. In the case of Covid-19, which is transmitted mostly by respiratory droplets, maybe that takes place somewhere in the lining of your nose or in the area of your lungs directly in contact with the air you inhale.

The virus then attaches to a cell via a protein on the cells surface called ACE-2 and lets itself in.

There, it begins to wreak havoc. The virus hijacks the cells machinery to make copies of itself. Those copies break out of the cell and then spread around your body. The copies enter more of your cells, make more copies, and so on. This is going viral, in the literal sense, and its a process your body works furiously to stop.

If the immune system is an orchestra in concert, its music can be broken down into two movements.

First, the opening: the innate immune response. This is the base-level protection you have to defend against infections even those your body has never seen before.

Iwasaki explains that every cell of your body has something of its own immune system in miniature. Your cells have a mechanism to detect virus infection, she says. Every cell is looking out for telltale genetic signs of viral replication. Once thats found, your cells start secreting these cytokines [signaling molecules] to tell the neighboring cells that theres a viral infection, she says. It will signal that cell to make a lot of antiviral proteins. Every part of the viral life cycle is targeted by hundreds of genes that are induced by this.

The innate immune response will then try to stop the virus in its tracks there, but it can fail, as we know. Viruses those sneaky bastards have evolved ways to counter this initial response. The viruses might encode proteins that degrade some of these signaling molecules, Iwasaki says. Even though we have this amazing system, viruses try to circumvent it.

If the innate immune system cant get rid of the infection, the second movement in this orchestration begins: the adaptive immune system. It has a vast array of instruments, each tuned to a specific task.

There are dendritic cells, which act as messengers from the innate immune system and tell the adaptive immune system which viral proteins it should seek out and destroy. There are killer T-cells, which hunt down and kill cells that have been infected. There are helper T-cells, which stimulate killer T-cells and recruit yet another class of cells called macrophages to gobble up infected cells, and they also stimulate B-cells, which bring this whole concert to a crescendo.

B-cells are critically important because they produce antibodies. These are little proteins that bind, specifically, to a single distinct part of a virus or pathogen and make it unable to hijack your cells. Antibodies can also identify invaders for other immune cells to destroy, and they can mark infected cells for destruction before a virus can burst out. And after an infection fades, the antibodies that linger can prevent the same virus from rising again.

But this process takes time.

When you first get infected with SARS-Cov-2, it usually takes anywhere from 10 to 14 days to make antibodies that are effective, says Vineet Menachery, an immunologist who studies coronaviruses at the University of Texas Medical Branch. That immunity actually peaks between four and eight weeks after youve been infected. The antibodies are really powerful at that point.

It takes a long time because an antibody has to be unique for the virus its trying to protect against. It takes a while and some trial and error to both build an antibody that can perfectly bind to the contours of the virus and to produce millions of copies of that antibody. The magnitude of potential antibodies is somewhere in the neighborhood of quadrillions or quintillions, Angela Rasmussen, a Columbia University virologist, says. But your immune system can narrow the choices down to the right formulation to clear the virus from your body.

The process isnt simple, but you can be in awe of it, like you can be in awe of a timepiece constructed from hundreds of delicately selected parts. I teach an entire semester course on this, Iwasaki says. This is the delicate process that a vaccine is trying to replicate artificially.

This antibody construction process can backfire, however. In some cases, antibodies bind to the virus, Iwasaki explains, and instead of blocking the virus, theyre taken up by white blood cells. Those white blood cells then go haywire, producing molecules called cytokines. Ordinarily, these chemicals promote inflammation throughout the body.

Inflammation is something that makes us feel sick, but it also helps us survive. People often think of swelling when they think of inflammation, Rasmussen says. Swelling occurs because cells from your immune system are rushing into the site of the infection. These immune cells have to get out of your blood vessels, she says, in order to corral the infection. Its a lovely process called rolling extravasation, she says. Your tissue gets inflamed because the balance of fluid is being changed.

But sometimes, so many cytokines are released that they trigger white blood cells to turn against healthy cells. That can then lead to organ failure and death. And that ultimately makes the disease as bad as it is, Iwasaki says.

Its unclear why a cytokine storm, as this reaction is called, might impact some people severely and not others, though there are indications that aging is a factor, as are underlying conditions like high blood pressure and diabetes. Researchers are also now looking for genetic clues to see who is most at risk. Thankfully, though, doctors do have some insights into how to treat this overreaction.

This whole orchestra ends when the immune system neutralizes all the virus in the body. That doesnt always mean the virus is purged; many viruses can linger in a latent state in the body without reproducing or causing symptoms. These latent viruses can flare up when the immune system is weakened, causing opportunistic infections. At the same time, youll be left with antibodies circulating in your blood.

But for reasons scientists dont quite understand, for some infections and notably, in other types of coronavirus infections antibody levels can wane over a period of years.

So how do doctors and scientists know if this process has been successful? How can they know if someone is now immune to the virus that causes Covid-19?

They test for it.

In particular, blood tests, also known as immunity tests or serological tests, can reveal who possesses antibodies to the virus. Deploying these tests will help answer a lot of questions. Most basically, it can help a person know if they have had Covid-19.

On a larger scale if deployed in well-designed studies serological tests could reveal the complete picture of the pandemic. They can also help scientists answer basic questions like:

Serological tests could also potentially allow people who have immunity to return to work. That could be a huge boost to front-line health workers who may have been exposed to the virus but are desperately needed back in action.

Just finding the antibodies isnt always enough, though. Scientists also need to do additional tests to make sure those antibodies are potent.

There are two main types of antibody tests, Menachery explains. The first just looks for antibodies and can be completed in a few hours. This is called an ELISA test (short for Enzyme Linked Immunosorbent Assay). And it doesnt provide the most complete picture of immunity.

The second test is more involved, and rarer. Its called a serum neutralization test, and it takes a few days to process. It not only looks for antibodies, it then exposes those antibodies to a virus in a cell culture to see how effective the antibodies are in stopping the virus.

Ideally, scientists will correlate the two tests and figure out which concentrations of antibodies confer the highest level of immunity. This work is ongoing, Menachery says. Its still not known what levels of antibodies are needed to have lasting, protective immunity. (What also remains to be shown: that the presence of antibodies also means you cant give the virus to someone else.)

These tests are useful, but they dont answer everything. As noted earlier, it takes days, if not weeks, for the body to produce antibodies. So a negative antibody test doesnt mean the virus isnt present. And since antibodies are produced during an infection and linger after its cleared, a positive antibody test doesnt mean that the virus is no longer active.

Confirming whether someone can still spread Covid-19 requires a separate genetic test like an RT-PCR test that detects the active virus.

Even if people do become immune, one thing we dont know about still is how long that immunity would last, Rasmussen says. And thats unfortunately not something we can determine until we wait months or years in the future, and test again and see if those antibodies are still there.

For reasons scientists dont quite understand, for some infections, your immunity never wanes. People who are immune to smallpox, for example, are immune for life: Antibodies that protect against smallpox have been found as long as 88 years after a vaccination.

Less reassuring here is that scientists have observed antibody levels to other coronaviruses (there are four coronavirus strains that infect people as the common cold) can wane over a period of years. A few weeks after an infection, antibody levels will be at their highest. But a year from now, that number is likely going to be a little bit lower, and five years from now its likely to be potentially a lot lower or a little bit lower, and we dont know the factors that change that, Menachery says.

However, even if you lose the antibodies, it doesnt mean you are again completely susceptible to the virus. Yes, none of this is simple.

There have been a few experiments where volunteers were willingly exposed to a coronavirus strain that produces a common cold. These studies show its common for the antibodies to these other coronavirus strains to decline after a year or so.

The majority of people that dont have serum neutralizing antibodies [i.e., antibodies that take out the virus], they get infected again, but they didnt get that sick, Menachery says. You couldnt do this type of test for Covid-19, he adds; its too dangerous.

There have been reports of a few patients out of China who had mild symptoms of Covid-19 who did not have detectable neutralizing antibodies after recovery, though they did have another form of antibody that binds to the virus. Its unclear whether they have protective immunity, Nature reports. Yes, there is more than one type of antibody, and they do different things, because none of this is simple.

Luckily, even if your antibodies against a coronavirus decline, your body has a backup plan.

Certain types of B-cells recall, these are the ones that make antibodies become memory B-cells. These save the instructions for producing a particular antibody, but they arent active. Instead, they hide out in your spleen, in your lymph nodes, perhaps at the original site of your infection waiting for a signal to start producing antibodies again.

With the memory B-cells in reserve, instead of waiting two weeks or more to get antibody production going, youll only have to wait maybe two or three days, Menachery says. So that means, yes, you can get infected again, but you may not even know youre sick. If you do get sick, maybe its a very minor infection.

Generally, he says, the more severe your infection, the more antibodies your immune system will produce, and the longer theyll stay in your bloodstream post-infection. So, he says, there is some concern that if you had a mild infection that your level of protection may not last long.

You may have seen some reports of people testing positive a second time for Covid-19 after recovering. The experts we spoke to say these reports are likely due to flaws in testing. I think the risk of being infected more than once from SARS-CoV-2 is nil, says Gregory Gray, an infectious disease epidemiologist at Duke University, in an email.

That may be because as you progress in the illness, the testing for Covid-19 becomes more inconsistent.

Often at the time that virus diseases present themselves, its fairly far into the replication of that virus in that person, says Diane Griffin, a professor of microbiology and immunology at the Bloomberg School of Public Health at Johns Hopkins University. Many symptoms of virus disease are actually manifestations of the immune response to the disease. Often things are starting to get better at the time youre starting to figure out someone even has a virus infection.

At least in the short term, its probably more the case that the people who have tested positive after recovering havent completely cleared the virus from their system or that a prior negative test was inaccurate.

Over the long term, the immune system itself becomes less effective with advancing age. And as people get older, they can acquire more chronic illnesses that can hamper the response to a virus, even if its one the immune system recognizes. It will be years, though, before scientists can understand what aging means for immunity to Covid-19.

The Centers for Disease Control and Prevention is now conducting serological surveys for Covid-19 antibodies in several places across the US.

Its an attempt to figure out who was previously infected with the virus, particularly if they never exhibited symptoms. A survey like this can show the actual background rate of infection and answer critical questions like what proportion of people have been infected without showing symptoms and where the virus has spread in a population, and quantify the overall rates of severe complications. Knowing these variables can help health officials better target interventions.

Many people who may have been infected also want to know if they are immune so they can safely leave lockdowns. Countries like Germany are even considering granting immunity passports so individuals can return to work.

Such testing could make a difference in a handful of cases, like for doctors and nurses who were infected or may have been exposed but are desperately needed back in action. But serological testing is unlikely to be a wholesale solution to reopening the economy.

Again, scientists are still uncertain about the robustness and duration of immunity that a Covid-19 infection confers, so a positive antibody test at this point doesnt guarantee that one can safely end social distancing measures. If immunity does fade after a year or two, the same person could be vulnerable to reinfection.

Meanwhile, to reopen schools, shops, and offices across the board, large numbers of people would have to have immunity. Without a vaccine, that would mean that the virus would have to infect vast swaths of the population, in the process sending thousands to the hospital and to their graves. That is exactly what measures like lockdowns and social distancing are trying to avoid.

While this outbreak has been ghastly, it has not been so bad as to bring about herd immunity in any quick time frame. There have been some imperfect serological studies that suggest the virus has infected more people than previously estimated. But even if true, the studies dont mean were anywhere close to achieving herd immunity.

So its unlikely that immunity can be a benchmark for when its okay to go back to normal across the population, and even in individual cases, it requires careful consideration of risks and benefits.

For those who have not yet contracted the virus, the main form of protection from Covid-19 right now is prevention. But there are several options scientists are studying that could help those who were never infected fend off the illness.

Chief among them is a vaccine. A vaccine can take various forms, including a weakened version of the virus itself, a small piece of the virus, or genetic material that prompts the immune system to manufacture antibodies to the virus.

Developing a vaccine for SARS-CoV-2 would be the ideal solution to the Covid-19 pandemic since its a form of prevention that would also hasten the end of costly measures like lockdowns, quarantines, and social distancing.

But its a time-consuming approach. Many experts estimate that it will take at least a year to develop a vaccine for the new coronavirus.

Vaccines can also pose risks. A small number of people can have dangerous adverse reactions to a vaccine, like severe allergies. In rare cases, vaccines can cause a phenomenon called immune enhancement, where the vaccine makes the recipients immune system overreact to the virus target, leading to a more severe disease than in those who were unvaccinated.

Though these risks are small, vaccines have to be delivered to millions of people. Thats why vaccine development focuses so much on safety and reducing the risks of complications as much as possible. Researchers are looking into various ways to speed up development, including human challenge trials where volunteers are deliberately exposed to the virus to test their immunity with and without a vaccine.

Another tactic under investigation is using convalescent plasma. The idea is to harvest the liquid part of blood, including proteins used for clotting, from people who have survived Covid-19. This plasma contains antibodies to the virus, so scientists are seeing whether it can help people with active infections get better. Researchers are also studying whether convalescent plasma can be used as a prophylactic to prevent Covid-19 in the first place.

Companies are also developing antibodies to SARS-CoV-2 using mice genetically engineered to have human immune systems. These antibodies can also be used to treat or prevent the disease.

But antibody transfusions, whether they come from Covid-19 survivors or were created in a lab, only confer protection against the virus for a few months.

The long-term strategy is to get enough people in a population immune to the virus so that it no longer spreads easily. This is known as herd immunity. It usually requires between 70 and 90 percent of a group of people to be immune in order to be effective, depending on the contagiousness of the virus.

With a large enough share of immunity in the population, even the remaining people who are not immune face a much lower likelihood of being infected. With few susceptible hosts in close proximity, pockets of infection quickly fade out. The question is whether this herd immunity is attained through vaccination or through infection.

The latter would not be ideal since it would involve millions getting sick from Covid-19. The United Kingdom was pursuing this approach back in early March but backed off its herd immunity strategy of limiting restrictions on movement and allowing people to be exposed. The country changed course when forecasters revealed that millions would likely contract the virus, overwhelming the UKs health system. Sweden has adopted a similar approach and is now facing vastly more Covid-19 cases than its neighbors.

Its also hard to gauge how close any country is to herd immunity since many people have likely been infected with the virus without knowing it. Figuring this out would require extensive testing for antibodies. And not everyone develops the same level of immunity from an infection. So vaccinating people against Covid-19 is the safer strategy.

Until then, widespread testing to identify the infected, isolating them, and tracing their contacts could help ease some of the pandemic control measures in place now.

How about what we can do as individuals?

Short of drugs like interferons, there isnt much a person can do to boost their immune system or their response to Covid-19, despite what various supplements promise.

The best Covid-19 approach for individuals is healthy habits maintain good hygiene, exercise, eat a balanced diet, get plenty of sleep, stay hydrated, manage any chronic health conditions like diabetes, and limit exposure to pollution.

Though the Covid-19 pandemic has been raging for several months, a lack of key information from how many people were infected to the origins of the disease continues to hamper the response.

More science on almost every aspect of this new virus is needed, but in this pandemic, as with previous ones, decisions with great consequences must be made before definitive data are in, wrote Harvard epidemiologist Marc Lipsitch in a column in the New York Times.

But the unknowns around immunity to the disease may be the most critical because they stand between the untenable present and a return to normal. Meanwhile, pressure is mounting to relax restrictions on movement to allow life to continue. With incomplete information, policymakers still have to make decisions that depend on immunity, but this can be done in ways that reduce risk.

The best approach is to construct a conceptual model a set of assumptions about how immunity might work based on current knowledge of the immune system and information about related viruses, and then identify how each aspect of that model might be wrong, how one would know and what the implications would be, Lipsitch wrote.

This is no easy task. It still might be the case that what we learn about immunity may not be enough for everything to go back to normal. We may need to wait, patiently, for a vaccine.

One advantage scientists have in the Covid-19 pandemic that they didnt have in prior outbreaks is an unparalleled level of information-sharing among researchers around the world. Researchers are posting their preliminary findings online for the world to scrutinize and working across borders, collaborating on an unprecedented scale.

That has led to unknowns becoming known faster than ever. But the disease is continuing to spread, and the drastic pandemic response measures cant continue forever, so some difficult choices lie ahead.

Support Voxs explanatory journalism

Every day at Vox, we aim to answer your most important questions and provide you, and our audience around the world, with information that has the power to save lives. Our mission has never been more vital than it is in this moment: to empower you through understanding. Voxs work is reaching more people than ever, but our distinctive brand of explanatory journalism takes resources particularly during a pandemic and an economic downturn. Your financial contribution will not constitute a donation, but it will enable our staff to continue to offer free articles, videos, and podcasts at the quality and volume that this moment requires. Please consider making a contribution to Vox today.

Read more from the original source:
Covid-19 immunity and testing, explained - Vox.com

Read More...

A possible new link between OCD and the immune system – Big Think

April 24th, 2020 5:48 pm

There has been a suspicion for some time that the immune system is somehow involved in the development of certain psychological disorders. Now a new study from Queen Mary University in London and led by Fulvio D'Acquisto has identified in mice a specific autoimmune protein that may trigger OCD's anxiety and stress in humans. "Our findings overturn a lot of the conventional thinking about mental health disorders being solely caused by the central nervous system," says D'Acquisto.

The study is published in Brain, Behavior, and Immunity.

Image source: Hanna Xu/unsplash

"There is mounting evidence that the immune system plays an important role in mental disorders," easy D'Acquisto. "And in fact, people with auto-immune diseases are known to have higher than average rates of mental health disorders such as anxiety, depression and OCD."

These potential linkages can be difficult to definitively affirm. Depression and anxiety, for example, may just as easily be understandable reactions to the autoimmune conditions' onset and not mental disorders. Still, as the study notes:

Image source: Kuttelvaserova Stuchelova/Shutterstock

At the heart of the new study's findings lies a protein the researchers call Immuno-moodulin, or Imood. An excess of this protein produced unusually anxious mice.

D'Acquisto and his colleagues stumbled across Imood by accident. Their intention was to investigate the role of another protein, Annexin-A1, in the development of multiple sclerosis and lupus. To that end, the researchers bred mice in which Annexin-A1 was being over-expressed in their immune systems' T-cells. Unexpectedly, these transgenic mice seemed more than typically anxious. Curious, the team analyzed the T-cells' genes and found one protein that was particularly active Imood.

The researchers' hunch was confirmed with the administering of an Imood antibody the mice calmed down in a few days.

Image source: Priscilla Du Preez/unsplash

Obviously, such findings in mice wouldn't necessarily apply to human beings. D'Acquisto's team decided to look for Imood in 23 OCD outpatients from the OCD tertiary outpatient Clinic of the University Department of Psychiatry of Milan, Policlinico Hospital. There were also 20 "normal" patients tested as a control group.

The researchers found the Imood amounts in the OCD patients were roughly six times higher than in the control group.

According to a Queen Mary University press release, D'Acquisto's research joins that of other scientists who identified the same protein as being over-expressed in patents with Attention-Deficit/Hyperactivity Disorder.

The mechanism behind the connection between Imood and OCD isn't yet clear. D'Acquisto suspects it's less a matter if direct alteration of brain function, and is more likely to be some influence exerted over brain cells already linked to mental disorders. He says, "This is work we still have to do to understand the role of Imood. "We also want to do more work with larger samples of patients to see if we can replicate what we saw in the small number we looked at in our study."

Related Articles Around the Web

Continue reading here:
A possible new link between OCD and the immune system - Big Think

Read More...

There’s an Emerging, Promising Link Between Exercise and Your Immune Health – POPSUGAR

April 24th, 2020 5:48 pm

Immune health is on our minds these days, which means you've probably been seeing lots of supplements, fancy foods, and special drinks touted as effective or natural ways to boost your immunity. The truth is that scientists haven't found a direct link between lifestyle changes and increased immune capacity, at least not yet. But there are still some intriguing correlations to explore, especially when it comes to exercise.

"Your immune system can improve when you work out," said Aruna Subramanian, MD, an infectious-disease doctor and clinical medical professor at Stanford. It's true: though research is still emerging, there's a link between increased immune health and exercise. One comprehensive 2019 review concluded that moderate to vigorous exercise, done in sessions of less than an hour, has a positive impact on your immune system, that moderate exercise is associated with a decreased risk of illness, and that exercise overall has an anti-inflammatory effect on your body. While the exact connection and reason are still considered inconclusive, working out regularly is clearly helpful to your body's line of defense.

The same review did note that unusually intense exercise could have the opposite effect, making you more susceptible to illness. In other words, it's better to stick with a more moderate routine if you're trying to follow the best path for your immune system, particularly if you're not used to high-intensity exercise. If you're a true beginner, start within your abilities and ramp up slowly. (This will also help prevent injuries.)

Exercise is also known to have significant psychological benefits, said Dean Winslow, MD, an infectious-disease doctor at Stanford Health Care, which can itself be good for your immunity. That's because chronic stress suppresses your immune system by increasing inflammation and creating an emotional strain that keeps you from your usual healthy habits (think: adequate sleep and eating healthy). Exercise of all kinds is recommended to relieve intense stress, another win-win way it can help your immune system.

So while the science is still being sorted out, keeping up your normal fitness routine, or slowly easing into a new one, can certainly be a positive for your immune system and your overall health. Try this month-long at-home workout plan to get started.

See more here:
There's an Emerging, Promising Link Between Exercise and Your Immune Health - POPSUGAR

Read More...

Harnessing the Human Immune System: Why Antibody Treatments Might Just Work Against COVID-19 – Cornell University The Cornell Daily Sun

April 24th, 2020 5:48 pm

In the race to develop a safe, effective treatment for COVID-19, biotech companies like Regeneron and Vir Biotechnology, led by Cornell alumni, have turned to antibodies which are naturally created by the human immune system as a form of therapeutic treatment.

But what are antibodies, and how can they be repurposed into drugs to help people recover from COVID-19?

Prof. Avery August, immunology, researches how the immune system responds to infection, and broke down each companys approach to antibody treatments and why they might work as a treatment for the coronavirus.

Antibodies are proteins made by specific cells in the immune system. The immune system produces antibodies when it comes into contact with something foreign to the body and then tries to identify that molecule or pathogen for the future, August said. These antibodies are used to target and stop any infections.

The antibodies are produced and then circulate in the blood, and act to protect you if you get exposed to that [foreign] thing again, August said. Antibodies are also what an individuals immune system produces in response to vaccines, which are dead or altered forms of a pathogen.

August noted that antibodies are especially useful because they can be collected from blood and used for antibody treatments.

Since antibodies are so large, they are difficult to chemically synthesize in a lab. So, antibodies produced for drug therapies are usually made by either bacteria or cell lines both have been genetically engineered to produce antibodies, according to August. Often, these antibodies are integrated into a mixture, usually referred to as antibody cocktails, that can be used as a treatment for viral infections.

Theyre made in these huge vats where the cells are grown andsecrete the antibodies, August said. The [secreted] fluid is collected, and the antibodies are then purified from that fluid and packaged as drugs.

August explained that since mice have an immune system similar to humans, scientists can utilize this similarity by exposing mice to a specific target, allowing the mice to develop an immune response, and then collecting the mices B cells.

B cells, or antibody-producing immune cells can then be grown in a culture, and antibodies specific to the desired target can be purified from the cells and used as a therapeutic.

However, this method of antibody production has one caveat.

The problem with using antibodies from mice is that a mouse antibody is slightly different from a human antibody, Avery said. You can use [them] as a drug, but eventually, humans start to make an immune response against the mouse antibody. So it stops working.

To overcome this hurdle, Regeneron and a few other biotech companies have genetically engineered mice to have a human immune system, so mice can directly produce human antibodies in response to a target.

According to Regenerons website, this is accomplished by replacing the genetic coding for a specific part of mouse antibodies with counterpart genes that are expressed in humans, allowing for the rapid and robust production of fully human antibodies.

Although this process of identifying, testing and producing antibodies as therapeutics can sometimes take years, Regenerons approach of using mice with human immune systems significantly accelerates the process because any identified antibodies can then be quickly converted into drugs for humans, August added.

In the pastwhen we didnt have these mice that have human immune systems, we had to generate the antibodies in mice, and then genetically engineer those antibodies so they look like human antibodies, which can take some time, and then make them into drugs, August explained.

In developing treatments for COVID-19, Regeneron is currently selecting antibody candidates to test a mixture of two antibody treatments for human clinical studies. The studies are slated to begin by early summer. Regeneron is also currently conducting clinical trials to evaluate the use of its drug Kevzara in the potential treatment of critical COVID-19 patients based on clinical data from China.

Vir Biotechnology has a different approach to developing antibody treatments. Instead of combining two antibodies in a mixture, Vir is selecting one antibody candidate and modifying it to allow for the antibodies to last longer in the body and produce white blood cells, which can lead to long-term immunity. In the search for antibody candidates, Virs goal is to find pan-coronavirus antibodies that could work in most future coronavirus outbreaks.

Regeneron and Vir also adopted the approach of isolating antibodies from the blood of humans who have already recovered from COVID-19.

According to August, there are two reasons for collecting blood from recovered coronavirus patients. One reason is that antibodies can be purified from the blood of those individuals and then be used to treat other humans.

However, using antibodies from recovered coronavirus patients has its limits. This treatment method is extremely expensive and it takes approximately two to four donors to treat one person, August said.

The second reason is that since the blood from recovered COVID-19 patients contain the B cells producing antibodies against the virus, those B cells can be identified and purified from the blood. Antibodies can then be genetically engineered in the lab to produce a drug people can use.

Although costly, antibody treatments are still a key player in the search for a drug that can treat COVID-19.

Small-molecule drugs are cheaper to make and easier to administer in the form of pills, but run the risk of losing their effectiveness if the virus mutates, August said. Antibodies are more likely to provide effective, longer-term protection since they specifically target the non-mutating regions of the virus, but need to be administered through injections.

While the course of this pandemic is uncertain, there is promise in antibody treatments. Mixtures of antibodies, usually referred to as antibody cocktails, have been instrumental in combating viral infections and have been the focus of Ebola treatment research.

Continued here:
Harnessing the Human Immune System: Why Antibody Treatments Might Just Work Against COVID-19 - Cornell University The Cornell Daily Sun

Read More...

Monitoring the immune system to fight COVID-19: CD4 status, lymphopenia, and infectivity – Science Magazine

April 24th, 2020 5:48 pm

30 April 2020

12:00 p.m. ET

Register now!

Andrea Cossarizza, M.D., Ph.D.

University of Modena and Reggio Emilia School of MedicineModena, Italy

Maurice OGorman, Ph.D., M.B.A., (D)ABMLI

Children's Hospital Los Angeles,Los Angeles, CA

Lishomwa (Lish) Ndhlovu, M.D., Ph.D.

Weill Cornell MedicineNew York, NY

Sean Sanders, Ph.D.

Science/AAASWashington, DC

The COVID-19 pandemic has struck the global population with unparalleled speed and ferocity. Researchers around the world are scrambling to learn about the biology, pathology, and genetics of SARS-CoV-2the novel coronavirus responsible for COVID-19while clinicians are seeking treatments, old and new, that might slow its infectivity and deadliness. In this webinar, we will explore what scientists are learning by using flow cytometry to study patients with COVID-19 in order to elucidate risk and disease severity. These experts are global leaders in cytometry and infectious disease, working on the frontlines of the COVID-19 outbreaks. They will provide concrete examples of how flow cytometry has been harnessed to provide key laboratory evidence that can be used in the fight against SARS-CoV-2 and COVID-19. Viewers will have the opportunity to put their questions to the expert panel during the live broadcast.

During the webinar, attendees will:

This webinar will last for approximately 60 minutes.

University of Modena and Reggio Emilia School of MedicineModena, Italy

Dr. Cossarizza completed his M.D. degree at the University of Padova in Italy before receiving a Ph.D. in oncology from the University of Modena and Reggio Emilia (UNIMORE) and the University of Bologna, also in Italy. After specializing in clinical pathology at UNIMORE, he obtained an associate professorship there. In 2005, he was appointed a professor in the international Ph.D. program at the University of Valencia in Spain, where he later became a research professor. In 2010, he became a full professor in pathology and immunology in the Faculty of Medicine at UNIMORE. He is a member of several editorial boards of international journals, and in 2016 was elected president of the International Society for Advancement of Cytometry. His primary research focus is identifying the molecular and cellular basis for the involvement of the immune system in diseases and infections, including HIV/AIDS and sepsis, as well as its role in pathophysiological conditions related to aging and neurodegeneration. Dr. Cossarizza has notable experience in the development and use of new flow cytometry approaches in immunological research.

Children's Hospital Los Angeles,Los Angeles, CA

Dr. OGorman earned his Masters and Ph.D. at the University of British Columbia before completing a postdoctoral fellowship at the University of North Carolina at Chapel Hill. He then joined the faculty at the Feinberg School of Medicine at Northwestern University, during which time he earned his MBA from Northwestern and served as vice chair of Pathology and Laboratory Medicine and director of Diagnostic Immunology and Flow Cytometry at Childrens Memorial Hospital in Chicago. He is currently chief of laboratory medicine, as well as director of the Clinical Lab and the Diagnostic Immunology and Flow Cytometry Laboratory at Childrens Hospital Los Angeles, and a professor of pathology and pediatrics at the Keck School of Medicine of the University of Southern California. Dr. OGormans research interests include immunopathogenesis of immune systemrelated disorders, investigation of immune mechanisms of immune suppression withdrawal in liver transplant patients, and the development of novel immune-related diagnostic laboratory tests. Additionally, he provides ad hoc reviews for multiple journals, including Cytometry,Journal of Leukocyte Biology, Journal of Immunological Methods, Clinical and Diagnostic Laboratory Immunology, and Archives of Pathology & Laboratory Medicine.

Weill Cornell MedicineNew York, NY

Dr. Ndhlovu is a professor of immunology at Weill Cornell Medicine in New York and principal investigator of the HIV and Emerging Pathogens Immunopathogenesis Laboratory in the Division of Infectious Diseases, also at Weill Cornell. A translational immunologist, he leads a research team dedicated to confronting the challenges of HIV and aging, with an emphasis on limiting disease complications and developing curative strategies. His program is now bringing the same urgency and focus to the COVID-19 pandemic, using both single-cell and epigenetic approaches to resolve molecular mechanisms regulating viral entry of SARS-CoV-2 infection across different tissues and cell types. His work seeks to identify therapeutic host targets and future therapies that reduce morbidity and mortality, and relieve the burden of this disease on society. Dr. Ndhlovu completed his undergraduate degree at the University of Zambia, his medical training at the University of Zambia Medical School, and his doctorate at Tohoku University School of Medicine in Japan.

Science/AAASWashington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Read the rest here:
Monitoring the immune system to fight COVID-19: CD4 status, lymphopenia, and infectivity - Science Magazine

Read More...

Coronavirus: Does ‘boosting’ your immune system really help fight off COVID-19? – Newshub

April 24th, 2020 5:48 pm

Does strong immunity help you fight off COVID-19?

COVID-19 is caused by the SARS-CoV-2 virus. Just like any foreign bug, the body will defend itself against the invader. Strong immunity is built on a healthy gut microbiome and an army of white blood cells. If someone is consuming a healthy diet based on an array of fruits, vegetables and wholefoods (foods in their whole and unprocessed form - e.g. a potato instead of fries), the immune system should be better-equipped to fight off the virus - or any illness, according to the Heart Foundation.

Hence, maintaining healthy immune function cannot be achieved by scoffing chips, biscuits and packaged dinners every day, "balanced" by a probiotic, Berocca and lemon water. It's built through a healthy lifestyle.

Vitamin C is widely touted for its immunity benefits, but if you're consuming enough fruit and veg, a supplement is unnecessary. Scientists in China are currently looking into whether ultra-high doses of vitamin C can help COVID-19 patients fight infection, but results will not be available until later this year.

In the meantime, the daily recommended intake can be achieved through citrus fruits, capsicum and greens such as broccoli and spinach. Unlike a pure vitamin C supplement, these foods also contain other vitamins and minerals that play an important part in keeping your immune system strong.

There are also three tried and trusted methods to supporting your immune system - reducing stress, getting enough sleep and exercising regularly.

Kombucha tastes great, it's trendy and there are a number of options on the market that are relatively inexpensive. However, it's not a magic tonic - and drinking it by the litre is not going to ward off COVID-19.

Like probiotics, kombucha contains live microorganisms. However, no studies have ever confirmed whether the drink has a high enough concentration to be considered a probiotic, and there is currently no evidence that kombucha can treat or prevent any illnesses.

To strengthen one's gut health and immunity, a far more pragmatic bet is opting for probiotic foods such as plain, unsweetened yoghurt, which is full of live cultures, and fermented products such as kefir and sauerkraut.

"There is no evidence to suggest that supplements labelled as immune-boosting such as green tea, zinc, elderberry or echinacea will provide any protection against COVID-19. Its more important to have a healthy lifestyle overall," Hursthouse wrote.

However, a vitamin D supplement can prove useful, particularly in parts of the world where sunshine is limited. Several studies have linked low vitamin D levels to a higher risk of respiratory infections. Vitamin D deficiencies are fairly common, and can be discovered through a blood test.

But again, if there isn't a deficiency, a supplement is not entirely necessary. As BBC Future reported in 2016, vitamin supplements typically don't provide any benefits in already healthy people.

And of course, prevention is always a good place to start. To minimise your chances of contracting COVID-19, follow the Ministry of Health's guidelines:

See the original post here:
Coronavirus: Does 'boosting' your immune system really help fight off COVID-19? - Newshub

Read More...

Coronavirus This Week: What is antibody testing and how it may impact the COVID-19 pandemic – Foster’s Daily Democrat

April 24th, 2020 5:48 pm

A great deal of discussion is taking place regarding antibody testing for the COVID-19 coronavirus. A basic discussion of immunology is helpful to understand the value of such testing.

What are antibodies? How do we develop antibodies? How do antibodies work? What is an antibody test? What are the clinical and public health benefits of antibody testing?

Antibodies are specialized humoral proteins made by the immune system. They help the body fight against infections and disease by "recognizing" viruses, bacteria and infected cells. Each antibody binds to a specific antigen associated with a danger signal in the body. This antigen is also known as the antibody's target. When a foreign protein like a virus enters the body, the immune system responds to this antigen. Specific proteins are developed to fight off and hopefully neutralize or kill the invader. This is technically called humoral immunity.

There are three ways to obtain immunity to various disease agents. Each of these will play a role as an antibody test for the COVID-19 coronavirus becomes widely used.

First is natural active immunity. This immunity is derived by naturally becoming infected by a pathogen, such as a virus or a bacteria. When infection occurs, humoral immunity kicks in, developing antibodies specific to this disease. When the body is exposed to this same pathogen (antigen) in the future, the immune system releases those specific antibodies to attack the pathogen before infection can take place. An example is a person developing a case of measles from exposure to the virus in the natural environment. This type of immunity is usually long-lasting. Unfortunately, not every infection with a pathogen results in developing antibodies that are protective or "neutralizing." For example, infection with the bacteria that causes Lyme Disease does not result in the development of protective antibodies, thus we can become reinfected with this bacteria upon repeated exposure.

Second is artificial active immunity. This type of immunity is developed by artificially exposing a person to a pathogen and causing the immune system to actively develop antibodies against this specific pathogen. This is accomplished through the process of immunization or vaccination. A vaccine, which is either a killed or very weakened version of the pathogen is introduced into a person, via injection, orally, nasal mist etc. When the vaccine (antigen) enters the body, the immune system actively begins to develop protective neutralizing antibodies against this specific pathogen (antigen). Normally, immunity begins about two weeks after immunization. With immunization, it may take multiple doses of the vaccine over time to develop a sufficient level of antibodies to confer full immunity. This type of immunity may not be long-lasting, requiring booster immunizations in the future. An example is tetanus, where after the initial series if immunizations to develop adequate immunity, this immunity may wane over the years requiring a booster "shot" every 10 years.

Third, and the least used method of providing immunity, is artificial passive immunity. This type of immunity is obtained when a serum collected from individuals who were naturally infected by and recovered from a specific disease and contains the antibodies against that disease, is administered to a non-immune person. The individual receiving this serum does not actively produce their own antibodies, but passively accepts and uses the artificially introduced antibodies from the donors serum to attack the pathogen and prevent infection. An example is the administration of immune globulin to susceptible individuals exposed to Hepatitis A. If given soon after exposure, this immune globulin containing antibodies against Hepatitis A will prevent infection and disease. This type of immunity is shorted-lived, usually providing only a few months of protection.

Each of these three methods of gaining immunity are being and will be utilized in various ways to combat the COVID-19 pandemic once a reliable antibody test is widely available to the medical and public health community. The FDA has recently licensed a number of these tests. The test must reliably be able to detect antibodies to the COVID-19 coronavirus, and that the level of antibodies in the person tested is sufficient to provide immunity. It usually takes about four weeks after infection to develop detectable antibodies to the COVID-19 coronavirus. Since this virus is so new, it is not yet fully understood how long such immunity will remain active, and if it will protect against the virus as it changes. If this virus behaves like similar coronaviruses, it is expected that immunity will develop for some period of time and that it will also be conferred against a changing virus.

The antibody test is already being used to identify individuals whom have developed immunity to COVID-19. This information will allow individuals, especially those in critical occupations such as health care, first responders and public safety to return to work more safely and quickly after infection and recovery. This will be expanded to other occupations as the testing becomes more widely used, to allow greater re-opening of the economy.

The test is also being used to identify individuals with antibodies to the COVID-19 coronavirus who would donate serum to be used to develop an immune globulin as described above. This serum globulin is being administered to critically ill COVID-19 patients to reduce symptoms and prevent death. Once available on a larger scale, more people with COVID-19 coronavirus antibodies will be recruited to donate serum to make larger quantities of this immune globulin that could be administered to susceptible individuals exposed to the virus, such as health care workers treating COVID-19 patients.

This antibody test will be used for public health surveillance and to determine how widely the COVID-19 epidemic has spread throughout the nation. Studies called sero prevalence studies will be conducted by testing large numbers of blood samples taken from people across the nation to better understand how much immunity to this virus exists. Blood will be tested from samples taken at blood donation centers, other clinical settings, and by recruiting a sufficiently large representative sample of the nation to volunteer. This information will determine which parts of the country have lower rates of immunity and may be more at risk if a second wave of disease strikes. This would provide information that will be used to prepare these at-risk areas before a second wave becomes a reality. This will allow better targeting and stockpiling of needed supplies and equipment in the areas where it may be most needed.

SEACOAST CORONAVIRUS NEWS IS FREE: This content is being provided for free as a public service to our readers. Sign up for our free daily or breaking email newsletters and Seacoast Health newsletter to stay informed. Please support local journalism by subscribing to Seacoastonline.com or by subscribing to Fosters.com.

Lastly, the antibody test will be used to evaluate the effectiveness of any vaccine developed for the Covid-19 coronavirus. As trial vaccines move through the safety and effectiveness stages for final approval, humans will be administered the trial vaccine on a voluntary basis. The antibody test will be used to determine if these trial vaccines develop sufficient protective antibodies to safely prevent infection. The test will also be used to determine how many doses of the vaccine will be required, at what intervals will doses be administered, how long immunity lasts, and if booster "shots" will be required and, if so, how long after initial immunization.

Unfortunately, all these steps will be taking place for at least the next year or two. We must expand diagnostic testing for the virus, conduct contract tracing to identify sources of community transmission, isolate cases and quarantine contacts. Face coverings must be required for everyone working or entering public places of business, and good hand hygiene must be maintained. In the meantime we will need to live with reasonable but necessary limits on our daily lives. The better we manage the crisis now, the better of we will be down the road.

Rich DiPentima of Portsmouth spent more than 30 years as a public health official and epidemiologist, including service as deputy public health director in Manchester and chief of communicable disease epidemiology at the New Hampshire Division of Public Health. His column on coronavirus will appear weekly in Seacoast Health during the coronavirus public health crisis.

View original post here:
Coronavirus This Week: What is antibody testing and how it may impact the COVID-19 pandemic - Foster's Daily Democrat

Read More...

Everything we know about coronavirus immunity, and plenty we still don’t – STAT

April 24th, 2020 5:48 pm

People who think theyve been exposed to the novel coronavirus are clamoring for antibody tests blood screens that can detect who has previously been infected and, the hope is, signal who is protected from another case of Covid-19.

But as the tests roll out, some experts are trying to inject a bit of restraint into the excitement that the results of these tests could, for example, clear people to get back to work. Some antibody tests have not been validated, they warn. Even those that have been can still provide false results. And an accurate positive test may be hard to interpret: the virus is so new that researchers cannot say for sure what sort of results will signal immunity or how long that armor will last.

They caution that policymakers may be making sweeping economic and social decisions plans to reopen businesses or schools, for example based on limited data, assumptions, and whats known about other viruses. President Trump last week unveiled a three-phased approach to reopen the country; he said some states that have seen declining case counts could start easing social distancing requirements immediately. And some authorities have raised the idea of granting immunity passports to people who recover from the virus to allow them to return to daily life without restrictions.

advertisement

Before we embark on huge policy decisions, like issuing immunity certificates to get people back to work, I think its good that people are saying, Hold up, we dont know that much about immunity to this virus, said Angela Rasmussen, a Columbia University virologist.

To be clear, most experts do think an initial infection from the coronavirus, called SARS-CoV-2, will grant people immunity to the virus for some amount of time. That is generally the case with acute infections from other viruses, including other coronaviruses.

advertisement

With data limited, sometimes you have to act on a historical basis, Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases, said in a webcast with JAMA this month. Its a reasonable assumption that this virus is not changing very much. If we get infected now and it comes back next February or March we think this person is going to be protected.

Still, the World Health Organization has stressed that the presumed immunity can only be proven as scientists study those who have recovered for longer periods. The agency is working on guidance for interpreting the results of antibody tests, also called serologic tests.

Right now, we have no evidence that the use of a serologic test can show that an individual is immune or is protected from reinfection, the WHOs Maria Van Kerkhove said at a briefing last week.

Below, STAT looks at the looming questions about antibodies and immunity that scientists are racing to answer.

What are antibody tests? How widely available are they? And how accurate?

The tests look for antibodies in the blood. Because antibodies are unique to a particular pathogen, their presence is proof the person was infected by the coronavirus and mounted an immune response. The hope is that the presence of the antibodies is an indication that the person is protected from another infection.

These are different from the tests used to diagnose active infections, which look for pieces of the virus genome.

Commercial antibody tests are starting to appear on the market, but so far, the Food and Drug Administration has only cleared a few through Emergency Use Authorizations. And already, health regulators are warning that the ones on the market may vary in their accuracy.

I am concerned that some of the antibody tests that are on the market that havent gone through FDA scientific review may not be as accurate as wed like them to be, FDA Commissioner Stephen Hahn said on Meet the Press earlier this month. He added that no test is 100% accurate, but what we dont want are wildly inaccurate tests.

Even the best tests will generate some false positives (identifying antibodies that dont actually exist) and some false negatives (missing antibodies that really are there). Countries including the U.K. have run into accuracy issues with antibody tests, slowing down their efforts for widespread surveys.

The fear in this case with imprecise tests is that false positives could errantly lead people to think theyre protected from the virus when they have yet to have an initial infection.

Serology testing isnt a panacea, said Scott Becker, the CEO of the Association of Public Health Laboratories. When its used, we need to ensure there are good quality tests used.

One specific concern with antibody tests for SARS-CoV-2: they might pick up antibodies to other types of coronaviruses.

Globally, there have only been a few thousand people exposed to the other coronaviruses that have caused outbreak emergencies, SARS and MERS. But there are four other coronaviruses that circulate in people and cause roughly a quarter of all common colds. Its thought that just about everyone has antibodies to some combination of those coronaviruses, so serological tests for SARS-CoV-2 would need to be able to differentiate among them.

What can be gleaned from serological results?

Detecting antibodies is the first step. Interpreting what they mean is harder.

Typically, a virus that causes an acute infection will prompt the bodys immune system to start churning out specific antibodies. Even after the virus is cleared, these neutralizing antibodies float around, ready to rally a response should that virus try to infect again. The virus might infect a few cells, but it cant really gain a toehold before the immune system banishes it. (This is not the case for viruses that cause chronic infections, like HIV and, in many cases, hepatitis C.)

The infection is basically stopped in its tracks before it can go anywhere, said Stephen Goldstein, a University of Utah virologist. But, Goldstein added, the durability of that protection varies depending on the virus.

Scientists who have looked at antibodies to other coronaviruses both the common-cold causing foursome and SARS and MERS found they persisted for at least a few years, indicating people were protected from reinfection for at least that long. From then, protection might start to wane, not drop off completely.

The experience with other viruses, including the other coronaviruses, has encouraged what Harvard epidemiologist Marc Lipsitch summed up as the educated guess in a recent column in the New York Times: After being infected with SARS-CoV-2, most individuals will have an immune response, some better than others. That response, it may be assumed, will offer some protection over the medium term at least a year and then its effectiveness might decline.

But many serological tests arent like pregnancy tests, with a yes or no result. They will reveal the levels (or titer) of antibodies in a persons blood. And thats where things can get a bit trickier. At this point, scientists cant say for sure what level of antibodies might be required for a person to be protected from a second Covid-19 case. They also cant say how long people are safeguarded, though its thought that a higher initial titer will take longer to wane than low levels.

Further investigation is needed to understand the duration of protective immunity for SARS-CoV-2, a committee from the National Academies of Sciences, Engineering, and Medicine wrote in a report this month.

Its not just whether someone is immune themselves. The next assumption is that people who have antibodies cannot spread the virus to others. Again, that hasnt been shown yet.

We dont have nearly the immunological or biological data at this point to say that if someone has a strong enough immune response that they are protected from symptoms, that they cannot be transmitters, said Michael Mina, an epidemiologist at Harvards T.H. Chan School of Public Health.

The challenge, as the National Academies report highlighted, is that no one knew about this virus until a few months ago. That means they havent been able to study what happens to people who recover from Covid-19 and if and how long they are protected for more than a short period of time.

One key uncertainty arises from the fact that we are early in this outbreak and survivors from the first weeks of infection in China are, at most, only three months since recovery, the report said.

What else can antibody tests show?

In addition to identifying those who have been infected, antibody tests can also suggest at a broader level how widely the virus has spread. These data have implications for how severe future outbreaks of cases might be and what kind of restrictions communities might need to live under. If more people have been infected than known a strong likelihood, given the number of mild infections that might have been missed and testing limitations in countries including the United States then more people are thought to be protected going forward.

In the United States, the Centers for Disease Control and Prevention and the National Institutes of Health have both launched serosurveys to assess how many people might have contracted the virus. Even employees of Major League Baseball teams have been enlisted in a study enrolling thousands of patients.

What have data from serosurveys shown thus far about antibody generation?

A number of countries have launched large serosurveys, so hopefully well have a better sense soon of the levels of antibodies being generated by individuals who recover from Covid-19 and among the general population. For now, though, there have only been limited data released from a couple small studies.

Scientists in Europe have pointed to strong antibody production in patients within a few weeks of infection. One study found that people were generally quick to form antibodies, which could help explain why the majority of people do not develop severe cases of Covid-19.

But one preprint released this month complicated the landscape. (Preprints have not been peer-reviewed or published yet in a research journal.) Researchers in Shanghai reported that of 175 patients with confirmed Covid-19, about a third had low antibody levels and some had no detectable antibodies. The findings suggest that the strength of the antibody response could correlate to the severity of infection, though thats not known for sure. They also raised concerns that those with a weaker antibody response might not be immune from reinfection.

But outside researchers have said that conclusions about immunity cant be drawn from what the study found. For one, there are different kinds of antibodies, so some might exist that the test wasnt looking for. Secondly, studies in other coronaviruses have shown that antibody responses vary from person to person, without clear implications for how protected someone is from another infection.

And, researchers say, antibodies are not the only trick the body has to protect itself. Immune cells also form memories after an initial infection and can be rallied quickly should that same pathogen try to strike again, even without antibodies or after antibody levels fade.

People that lose that serum neutralization it doesnt mean necessarily that theyre not going to have some level of immunity, said virologist Vineet Menachery of the University of Texas Medical Branch. Your immune system hasnt forgotten. It may just take them a couple of days to generate that immune response and be able to clear a virus.

He added that its likely that if and when protection starts to wane and people contract the coronavirus a second time, its likely to cause an even milder illness.

Ive heard reports of reinfection or reactivated virus. Whats going on there?

Health officials in some countries have said theyve seen examples of people recovering from Covid-19 only to test positive for the virus again what theyve taken to calling reactivation, to differentiate it from a second infection.

But experts are skeptical that either is occurring.

While no possibility can be eliminated at this early stage of the outbreak, they say that there are more likely explanations for a positive diagnostic test coming after a negative test.

For one: The tests used to diagnose Covid-19 look for snippets of the virus genome, its RNA. But what they cant tell you is if what theyre finding is evidence of live virus, meaning infectious virus. Once a person fights off a virus, viral particles tend to linger for some time. These cannot cause infections, but they can trigger a positive test. The levels of these particles can fluctuate, which explains how a test could come back positive after a negative test. But it does not mean the virus has become active, or infectious, again.

And two: the diagnostic tests typically rely on patient samples pulled from way back in their nasal passages. Collecting that specimen is not foolproof. Testing a sample that was improperly collected could lead to a negative test even if the person has the virus. If that patient then gets another test, it might accurately show they have the virus.

As Jana Broadhurst, the director of the Nebraska Biocontainment Units clinical laboratory, said, garbage in, garbage out.

Sharon Begley contributed reporting.

See more here:
Everything we know about coronavirus immunity, and plenty we still don't - STAT

Read More...

CHI, the Cleveland Health Institute – Cleveland Jewish News

April 24th, 2020 5:47 pm

CHI, the Cleveland Health Institute, is dedicated to delivering health care with compassion, humility and integrity. We offer a full spectrum of services ranging from triaging acute care to diagnosing and managing chronic illness to practicing precise personalized medicine. We do this by emphasizing gene compatible lifestyles through predictive testing, preventive measures, personalized programs and patient education, enabling true partnership and full participation in creating health.

We have adopted the following in order to continue to care for our staff and CHI patients:

Telemedicine for scheduled consultations and follow up appointments

Secure email or fax for all administrative forms, patient histories and lab requisitions

Mail test kits with pre-paid labels to ship directly to labs

COVID-19 prevention recommendations and kit

Ship directly to our patients or provide curb side pickup for pharmaceutical grade targeted nutritional support for the immune system or to balance your neuroendocrine system to help with fear, anxiety, fatigue or depression

Emergency patient phone service 24/7

Upgrading CLE-CHI.com featuring an online store, contact us and ask your questions and the library of current relevant featured articles, like COVID 29 and Creating Maximum Immunity: A Vaccine will not Cure the Problem

Dr. Tonya S. Heyman, Medical Director

Here is the original post:
CHI, the Cleveland Health Institute - Cleveland Jewish News

Read More...

Personalized Medicine Market Is Projected To Expand At A Robust CAGR Of +11% By 2026 Analysis by Industry Outlook, Estimated Size, Valuable Share,…

April 24th, 2020 5:47 pm

Personalized medicine companies seek to combat the scourge of cancer through personalized care, driving interest in patient-specific treatments that require testing.

The global personalized medicine (PM) market size was estimated at USD 1.57 trillion in 2018 and is anticipated to expand at a CAGR of +11% during the forecast period.

Personalized medicine promises a paradigm shift in diagnosis and care delivery as the treatment is based on data leveraged from a holistic view of an individual patient. Proliferation of sequencing methodologies, especially Next Generation Sequencing (NGS), due to rising cost of sequencing and development of Human Genome Project in genomics field is expected to drive the market.

Get Sample Copy of this Report Includes @: https://www.theresearchinsights.com/request_sample.php?id=45572

Key players profiled in the report include GE Healthcare; Illumina, Inc.; Asuragen, Inc.; Abbott Laboratories; Dako A/S; Exact Science Corporation; Danaher Corporation (Cepheid, Inc.);Decode Genetics, Inc.;Genelex Corporation; Exagen Diagnostics, Inc.; Precision Biologics, Inc.; QIAGEN; Celera Diagnostics LLC; and Biogen, Inc.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Personalized Medicine market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

In the geographic segmentation, the regions such as North America, Middle East & Africa, Asia Pacific, Europe and Latin America are given major importance. The top key driving forces of Personalized Medicine market in every particular market is mentioned with restraints and opportunities. The restraints are also given a counter act which prove to be an opportunity for this market during the forecast period of 2020 to 2026 respectively.

Get Discount on up to 40%: https://www.theresearchinsights.com/ask_for_discount.php?id=45572

Personalized Medicine market is also explained to the clients as a holistic snapshot of a competitive landscape within the given competitive forecast period. A comparative analysis of regional players and segmentations, which helps readers get a better understanding of the areas and resources with better understanding.

This report provides:

1) An overview of the global market for Personalized Medicine Market and related technologies.

2) Analyses of global market trends, with data from 2017, estimates for 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2026.

3) Identifications of new market opportunities and targeted promotional plans for Global Personalized Medicine Market.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.

Table of Content

1 Introduction

2 Market Research Tactics

3 Market Summary

4 Quality Market Insights

5 Personalized Medicine Market Overview

6 Regulatory Market Synopsis

7 Personalized Medicine Market, By Application Analysis:

8 Personalized Medicine Market, By product Analysis:

9 Personalized Medicine Market, By End User Analysis:

10 Personalized Medicine Market, By Geographic Region

11 Competitive Landscape

12 Company Profiles

You Can Browse Full Report: https://www.theresearchinsights.com/enquiry_before_buying.php?id=45572

About usThe Research Insights A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact usRobinSales manager+91-996-067-0000[emailprotected]

Continue reading here:
Personalized Medicine Market Is Projected To Expand At A Robust CAGR Of +11% By 2026 Analysis by Industry Outlook, Estimated Size, Valuable Share,...

Read More...

Coronavirus: New plan would test 30 million per week and cost up to $100 billion, but ‘we’ve got to do it’ – CNBC

April 24th, 2020 5:47 pm

Dr. Natalia Echeverri, (R) uses a swab to gather a sample from the nose of Sammy Carpenter, who said he is homeless, to test him for COVID-19 on April 17, 2020 in Miami, Florida.

Joe Raedle | Getty Images

An ambitious new plan to radically increase the number of coronavirus tests in the United States would see up to 30 million people screened each week and cost up to $100 billion to implement, a private foundation said Tuesday.

But that pricey effort for what one expert called "the largest public health testing in history" is necessary to stem the $300 billion to $400 billion in American economic losses each month as a result of the Covid-19 pandemic, the Rockefeller Foundation said.

It said the sooner coronavirus tests become much more widely available, the quicker the U.S. economy can start getting back to normal.

"We do have the capacity to do that, and we've got the resources to do that," said Dr. Michael Pellini, managing partner of health venture firm Section 32 and board member of the Personalized Medicine Coalition, who contributed to the foundation's new plan.

"Yes, it's ambitious, but at this point we've got to do it," Pellini said. "We have to fix testing in this country to enable our workforce to be deployed once again."

The plan comes amid calls by numerous experts and by CEOs to boost coronavirus testing to make sure businesses and social events can reopen safely without sparking second and third waves of virus outbreaks.

Amazon CEO Jeff Bezos, in a note to shareholders last week, wrote:Regular testing on a global scale, across all industries, would both help keep people safe and help get the economy back up and running."

Rockefeller Foundation President Dr. Rajiv Shah said: "We envision an America where everyone who needs a test can get one."

Rajiv Shah, president of The Rockefeller Foundation

Jason Alden | Bloomberg | Getty Images

"The Rockefeller Foundation believes that testing access is critical to scaling up our lives and economy," Shah said during a conference call with reporters Monday, when the total number of confirmed coronavirus cases reached more than 766,600, and the number of related fatalities approached 41,000.

He called the up-to-$100 billion cost of the effort "a modest investment," given the amount of monthly economic losses to the nation, as well as the societal costs related to the outbreak, which could end up increasing rates of suicides, alcoholism and domestic violence.

While the goal of the testing plan is to build a state-led national program, the foundation said funding for it likely can come from federal funds through agencies or grants.

The foundation itself is investing $15 million to help kick off the effort, which includes supporting cities that are among the first to adopt the plan's recommendations.

The Rockefeller Foundation,which is a major philanthropicdonorin areas including health and science, told CNBC last week that it had been in contact with the Trump administration, national groups of governors and mayors and leading American corporations as it prepared the recommendations.

The foundation's plan lays out a strategy for tripling, within the next eight weeks, the existing 1 million coronavirus test per week now being done by maximizing efficiencies in testing capacity.

After that, the foundation calls for multiplying those 3 million tests per week by at least 10 times to get to at least 30 million tests each week within the next six months.

Reaching that level will entail, among other things, removing regulatory barriers to approval for new point-of-care and home-test kits, and ensuring payments for labs performing the tests.

The Rockefeller plan says that more testing must be done to accurately capture the level of Covid-19 infections in the U.S.

"In Taiwan, there have been 132 tests conducted for every confirmed case. In Australia, the number is 62. In the United States, it is five," an executive summary of the plan notes.

"The unfortunate conclusion from this comparison is that the country's actual number of infections may be 15- to 20-times higher than the reported number of confirmed cases," the summary says.

"In short, the United States needs to increase the current level of 1 million tests per week by at least 10-fold and preferably 20-fold to adequately monitor the pandemic."

The plan notes that "given the commercial uncertainties inherent in this 10-fold increase in production" it is likely the federal government would need to activate the Defense Production Act to compel production of tests.

The plan calls for the creation of an Emergency Network for Covid-19 Testing to coordinate and underwrite the testing market with the use of leverage from public-private credit guarantees and other tools.

The second part of the plan envisions a paid Covid Community Healthcare Corps of 100,000 to 300,000 people to perform the high number of texts and conduct "contact tracing," or reaching out to individuals who have been around infected people and testing them as well.

The third part is a common data and digital platform to support the first two objectives by sharing "real-time analyses of resource allocations, disease tracing results and patient medical records."

New York University professor Paul Romer, who shared the 2018 Nobel Prize in economics, said the need for a huge increase in the number of coronavirus tests is driven not only by the need to stanch current economic losses but to prevent permanent damage to U.S. economic output when the country exits recession.

"Our future capacity to produce" is lower because of the economic cost of the pandemic "and it deteriorates with each month of delay," said Romer, who contributed to the Rockefeller Foundation's plan.

But Romer said the solution to the testing problem lies in the current system, which needs to be reorganized and incentivized financially to produce enough tests.

"We're really not constrained on the supply side, but we are constrained by what we're willing to pay," Romer said.

"We just need to pay people and let them have to option to provide these tests."

Romer made the analogy of the government saying that there needed to be 300 million soft drinks made one day.

No one would step up to make the drinks for free, he suggested, but they would be made if the government agreed to pay for them.

See the rest here:
Coronavirus: New plan would test 30 million per week and cost up to $100 billion, but 'we've got to do it' - CNBC

Read More...

Page 582«..1020..581582583584..590600..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick